Topics in Medicinal Chemistry

Proteinkinase Inhibitors

Editors: Laufer, Stefan A. (Ed.)

Free Preview
  • Reviews proteinkinase inhibitors
  • Exploits kinase inhibitors for cancer treatment
  • Offers an authoritative perspective from industry and academia
see more benefits

Buy this book

eBook 93,08 €
price for Spain (gross)
  • ISBN 978-3-030-68180-7
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover 114,39 €
price for Spain (gross)
  • ISBN 978-3-030-68179-1
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
About this book

This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book.

Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.


About the authors

Stefan Laufer is a Professor of Pharmaceutical/Medicinal Chemistry at Tuebingen University, Germany, and he had previously worked for 10 years in the Pharmaceutical Industry. His research interests are anti-inflammatory and cancer drug discovery with various eicosanoid (COX-1,2,3, LOXs, mPGES1, cPLA2) and protein kinase targets (p38, JAKs, JNKs, CK1d, mtEGRFs). Three compounds from his lab entered clinical development phases. Dr. Laufer chairs the ICEPHA (Interfaculty Center for Pharmacogenomics and Drug Research) and TüCADD, Tuebingen Center for Academic Drug Discovery. As part of this work, a proprietary kinase inhibitor collection is established (TüKIC, 10.000 cpds). He authored more than 500 publications, 14 books/bookchapters, and is inventor in 42 patent families.

Table of contents (8 chapters)

Table of contents (8 chapters)

Buy this book

eBook 93,08 €
price for Spain (gross)
  • ISBN 978-3-030-68180-7
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover 114,39 €
price for Spain (gross)
  • ISBN 978-3-030-68179-1
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
Loading...

Bibliographic Information

Bibliographic Information
Book Title
Proteinkinase Inhibitors
Editors
  • Stefan A. Laufer
Series Title
Topics in Medicinal Chemistry
Series Volume
36
Copyright
2021
Publisher
Springer International Publishing
Copyright Holder
Springer Nature Switzerland AG
eBook ISBN
978-3-030-68180-7
DOI
10.1007/978-3-030-68180-7
Hardcover ISBN
978-3-030-68179-1
Series ISSN
1862-2461
Edition Number
1
Number of Pages
VII, 256
Number of Illustrations
1 b/w illustrations
Topics